U.S. Government and Novavax Extend Partnership
Monday, February 13, 2023
Novavax announced a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defence, to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373).
This agreement will maintain the U.S. public's access to Novavax' vaccine and support the development of smaller dose vials, strain selection in line with U.S. Food and Drug Administration (FDA) recommendations, and a smooth transition to the commercial market.
This contract will support the U.S. government's continued efforts to make Novavax' protein-based vaccine available for free to states, jurisdictions, federal pharmacy partners and federally qualified health centres.
This agreement offers the American people a diverse COVID-19 vaccine portfolio and underscores the importance of Novavax' partnership with the U.S. government to ensure continuous access to a protein-based option as part of public health measures. This collaboration with the U.S. government on the development of COVID-19 vaccine will meet the requirements of the FDA and the commercial customers for the upcoming 2023/2024 vaccination campaign.
